A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza) + RVD (Lenalidomide [Revlimid] + Bortezomib [Velcade] + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma

Trial Profile

A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza) + RVD (Lenalidomide [Revlimid] + Bortezomib [Velcade] + Dexamethasone) for Patients With Newly Diagnosed Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Lenalidomide (Primary) ; Vorinostat (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Feb 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
    • 06 Feb 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
    • 18 Jan 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top